Emergent BioSolutions Inc.
EBS•NYSE
Emergent BioSolutions Inc.
EBS•NYSE
Mkt Cap$546.23M
Sentiment
Phase 1 · Company Overview
Step 1: Overview
What the company does, where it operates, and who runs it.
Overview for Emergent BioSolutions Inc.
Industry:Drug Manufacturers - Specialty & Generic
Sector:Healthcare
CEO:Joseph C. Papa Jr.,
Description:Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Address:400 Professional Drive, Gaithersburg, MD, US
Step 2: Infographics
Visual summary of the business at a glance.
Phase 2 · FRC Research
Step 3: Media
Videos and interviews covering the company.
Phase 3 · Financial Data
Step 4: Stock Data
Price chart, volume, and trading data.
EBS Stock Price
Step 5: Fair Value
What FRC thinks the stock is worth vs. the current price.
Step 6: Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Step 7: Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Step 8: Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Step 9: Financial Statements
Income statement, balance sheet, and cash flow statements.
Phase 4 · Peer Comparison
Step 10: Comparables
List of peer companies in the same industry.
Phase 5 · Ownership & News
Step 12: Institutional Ownership
Which funds and firms own the stock.
Step 13: Insider Trading
Recent buying and selling by company executives.
Step 14: Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
Step 15: News
Latest headlines and market coverage.
News
Latest Market News